SHANGHAI, July 27, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer, will participate in the upcoming investor conferences.
2nd Annual Evercore China Biotech Summit Date: Tuesday, August 18, 2026 Time: 11:00am HKT Format: Presentation and Q&A Location: The Ritz-Carlton Shanghai, Pudong
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.
Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
MUMBAI, India, July 27, 2026 /PRNewswire/ — What happens when colour is viewed not simply as a trend, but as a story shaped by material, craft, memory and design? Asian Paints brings its yearly forecast ColourNext 2026 into the world of collectible designfor the first time with ‘Colour As Continuum’ displayed at Nilaya Anthology, Mumbai.
Asian Paints Colour As Continuum at Nilaya Anthology
Presented as a month-long curated design experience, the showcase reimagined the four ColourNext 2026 directions, IRL, Pastoral, Solarpunk and Daydream, through a carefully selected collection of furniture, objects and material expressions from Nilaya Anthology’s enviable roster of designers and makers. Moving beyond traditional trend forecasting, it invited visitors to experience Colour through stories, emotions and material explorations.
Over the last two decades, ColourNext has evolved into South Asia’s most deeply researched colour and material forecast, examining colour as a reflection of changing lifestyles, material innovations and emerging ways of living. At the heart of ‘Colour As Continuum’ is the idea that colour is never experienced in isolation. Through a curation of collectible design pieces, visitors discovered how colour is shaped by materials, craftsmanship and cultural memory. Each curated space brought to life the tactile warmth of IRL, craft traditions of Pastoral, the regenerative vision of Solarpunk and the softness of Daydream. Objects designed by Charlotte Perriand, Le Corbusier, Pierre Jeanneret, Christoph Delcourt, Christabel McGreevy, Ashiesh Shah, Ravi Vazirani, Paola Paronetto, Laura Pasquino, Jacqueline Leighton Boyce and more are curated across the four forecast directions.
It also features Colournext Lab where biomaterials, woven fibres, handcrafted processes, translucent surfaces and experimental finishes demonstrated how material carry emotion, ecology and cultural continuity.
Speaking about ColourNext, Amit Syngle, MD & CEO, Asian Paints, said, “ColourNext has evolved into a cultural document that studies how shifts in society, technology, craft and human behaviour begin to shape the spaces we inhabit.With Colour As Continuum, we have taken ColourNext beyond trend forecasting into a curated collectable design experience at Nilaya Anthology.”
As part of the programme, Nilaya Anthology hosted the launch of Udayshanth Fernando: Living Design, a new publication by Rizzoli USA, alongside an evening with London-based artist HARRI exploring material innovation and the future of design. Visitors could also trace ColourNext’s evolution since 2003 through archival storytelling and its CMFT narrative.
Colour As Continuum was showcased at Nilaya Anthology until July 2026.
The round brings HiDream.ai’s total financing over the past three months to more than RMB 2.1 billion and marks its entry into unicorn status
BEIJING, CHINA – Media OutReach Newswire – 27 July 2026 – HiDream.ai, a global large-model AI technology company, has announced the completion of a RMB 1.5 billion Series C financing round. The round was co-led by the National Social Security Fund Sichuan Revitalization Sci-Tech Innovation Fund, ICBC Capital, Hongyi Asset Management and Dunhong Capital.
The screenshot of this leaderboard was taken on June 22, 2026.
New investors including Xiamen ITG Capital, Shanghai Film New Vision Fund, Hubei Yangtze River Industry Investment Group, Huace Film & TV, Hangyuan Capital, Chuangyunhai Capital, Huafu Investment, Yuhang Financial Holding, Bank of Communications Capital and Wakamatsu Fund also participated. Existing shareholders including Hefei Industrial Investment, Fortune Capital, Kingpo Investment, Jinhua Capital, Zhongzhe Capital and Caixin Capital continued to back the company.
The round brings together national-level long-term capital, regional government-backed investment platforms, industry investors and venture capital firms. HiDream.ai said the funding will support its development of native omni-modal world models and the expansion of its product and commercial ecosystem.
The Series C follows two earlier rounds completed within the past three months, bringing HiDream.ai’s total financing during the period to more than RMB 2.1 billion. With the latest round, the company has entered unicorn status.
“Forward-looking judgment on AI technology and continued innovation in large-model architecture have always been core to HiDream.ai’s growth,” said Mei Tao, founder and CEO of HiDream.ai. “We believe the evolution from multimodal AI to native omni-modal world models is an essential path toward AGI. With this funding, we will continue building the foundation for native omni-modal world models and work with global developers and partners to expand the boundaries of intelligence.”
Long-term Capital Backs HiDream.ai’s AI Roadmap
The round includes national-level long-term capital, technology-focused financial investors and multiple regional government-backed investment platforms.
The participation of the National Social Security Fund Sichuan Revitalization Sci-Tech Innovation Fund as a co-lead investor reflects growing institutional support for foundational AI technologies and critical AI infrastructure.
Regional investment platforms including Hefei Industrial Investment, Xiamen ITG Capital, Yuhang Financial Holding and Hubei Yangtze River Industry Investment Group also participated or increased their exposure, providing support across capital, industrial resources and application scenarios.
Existing shareholder Hefei Industrial Investment has backed HiDream.ai across three consecutive rounds, underscoring long-term confidence in the company and its alignment with Hefei’s strategy to develop a hard-tech and AI innovation hub.
HiDream.ai said support from long-term institutional capital and regional government-backed investors will help provide full-cycle backing for model research, product development and industrial deployment.
Industry Investors Deepen Content and Entertainment Partnerships
The Series C round also introduced leading film and entertainment industry investors, including Shanghai Film New Vision Fund and Huace Film & TV.
HiDream.ai said these partnerships will expand its access to film and entertainment resources, production scenarios and high-quality content data, supporting innovation in AI-native content production.
The company has been working with Shanghai Film Co., Ltd. on next-generation content production, cinema scenario upgrades, AI-powered cross-screen marketing, and AI-enabled large-screen production standards and workflows.
HiDream.ai also plans to collaborate with Huace Film & TV on AI agent-assisted content creation, corpus co-development, premium content co-production and full-chain IP development.
Together with earlier cooperation with Hubei Yangtze River Film Group, the addition of Shanghai Film New Vision Fund and Huace Film & TV further expands HiDream.ai’s role in China’s film and entertainment ecosystem and provides richer data and application scenarios for its video models.
From Native Omni-modal Models to World Models
HiDream.ai is among China’s earliest companies focused on multimodal generative AI. Built on its self-developed HiDream model family, the company has developed a portfolio of AI products and a global commercial network across content creation, marketing, and film and entertainment production.
Earlier this year, HiDream.ai’s native omni-modal HiDream-O1 model series, based on its original UiT, or Unified Transformer, architecture, achieved leading results on the text-to-image leaderboard of Artificial Analysis, a global independent AI model evaluation and analytics platform. The open-source version ranked first globally, while the closed-source version ranked among the global top three, positioning HiDream.ai among the leading players in visual generative AI.
At the product and commercialization level, HiDream.ai is pursuing a dual-engine strategy combining foundation models and AI agents. Built on the HiDream-O1 model series, its “1+1+3” framework includes one foundation model, one Token Hub platform for standardized model capability output, and three application areas: commercial marketing, film and entertainment production, and content creation.
At WAIC 2026, HiDream.ai introduced vivago R1, a multimodal creative agent with long-form video generation and editing capabilities. The “R” in R1 stands for long-horizon reasoning, reflecting a shift in AI-assisted creative production from generating isolated assets to planning, orchestrating and executing longer creative workflows.
HiDream.ai’s products currently serve users in more than 100 countries and regions, including over 50 million professional users and more than 40,000 enterprise customers. The company said these commercial deployments validate the practical application of its native omni-modal architecture and provide a foundation for future scale.
HiDream.ai said its long-term vision is to move from multimodal AI to omni-modal AI and ultimately world models — systems capable of understanding, reasoning about and constructing dynamic environments. The company will continue advancing both large-model technology and AI agent products, accelerating the shift of AI from a tool to an intelligent partner.
Hashtag: #HiDreamAI
The issuer is solely responsible for the content of this announcement.
About HiDream.ai
HiDream.ai is a large-model AI technology company focused on native omni-modal intelligence and world-model development. Built on its self-developed HiDream model family, the company develops foundation models, AI agent products and AI applications across commercial marketing, film and entertainment production, and content creation.HiDream.ai’s products serve users in more than 100 countries and regions, including over 50 million professional users and more than 40,000 enterprise customers.
Award strengthens NANO Nuclear’s growing relationship with the Department of the Air Force and expands the Company’s pathway toward future defense deployment opportunities.
New York, New York – Newsfile Corp. – July 27, 2026 – NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), today announced it has been selected by AFWERX for a SBIR Phase I contract focused on NANO Nuclear’s KRONOS MMR™ Energy System to address the most pressing challenges in the DAF. The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018 which expanded the range of innovations the DAF funded and now on July 21, 2026, NANO Nuclear Energy will start its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America.
James Walker, Chief Executive Officer of NANO Nuclear Energy, said: “This award represents another meaningful step in the continued advancement of NANO Nuclear’s defense commercialization strategy. We now have multiple active engagements with the Department of the Air Force that demonstrate increasing confidence in our technology and technical capabilities. We believe these programs create valuable opportunities to showcase the KRONOS MMR™, while establishing relationships that may support future deployment opportunities across additional Air Force installations and the broader Department of War.”
Jay Yu, Founder and Chairman of NANO Nuclear Energy, added: “Energy resilience has become a strategic priority across the U.S. military, and advanced microreactors have the potential to fundamentally change how critical installations are powered. This award is significant not only because it expands our opportunity with the Air Force, but because it represents continued commercial validation of our technology roadmap. As we continue executing on each of our Air Force programs, we believe NANO Nuclear is positioning itself as an emerging participant in what could become one of the most important long-term markets for advanced microreactor deployment.”
The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of War, or the U.S. government.
About NANO Nuclear Energy, Inc.
NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.
Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include the proprietary KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, “ZEUS”, a portable solid core battery reactor, and the space focused, portable LOKI MMR™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.
Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.
HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.
NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.
The Air Force Research Laboratory is the Department of the Air Force’s primary scientific research and development center and one of six centers within Air Force Materiel Command. AFRL leads the discovery, development and delivery of technologies for air, space and the multidomain. With a workforce spanning seven mission areas at more than 40 locations worldwide, AFRL conducts research ranging from basic science to advanced technology development.
About AFWERX
As the innovation arm of the Department of the Air Force and a division within the Air Force Research Laboratory, AFWERX brings American ingenuity from small businesses and startups to solve the most pressing challenges facing Airmen and Guardians. Headquartered at Wright-Patterson Air Force Base, Ohio, AFWERX strengthens the defense industrial base by expanding access to nontraditional vendors, building new defense partnerships and accelerating the transition of critical technologies to operational capability. In fiscal year 2025, AFWERX awarded more than 1,000 contracts totaling $1.37 billion and achieved 438 Phase III transitions valued at $8.1 billion, supercharging the industrial base that supports U.S. military readiness and battlefield advantage.
For further NANO Nuclear information, please contact: Email: IR@NANONuclearEnergy.com Business Tel: (212) 634-9206
PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE: NANO Nuclear Energy LINKEDIN NANO Nuclear Energy YOUTUBE NANO Nuclear Energy X PLATFORM
This news release and statements of NANO Nuclear’s management and collaborators in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “explore,” “plans”, “aim,” “goal,” “believes”, “potential”, “will”, “should”, “could”, “would” or “may” or derivations of these words and other words of similar meaning about the future. In this press release, forward-looking statements include those relating to the anticipated benefits to the Company of the AFWERX award described herein and the future development and deployment of the KRONOS MMR™ Energy System generally. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy (“DOE”), U.S. Nuclear Regulatory Commission (“NRC”), Canadian Nuclear Safety Commission (“CNSC”) or related state or other U.S. or non-U.S. nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain contracts and funding to be able to continue operations, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
The issuer is solely responsible for the content of this announcement.
HEIDELBERG, GERMANY – Newsaktuell – 27 July 2026 – It is with deep sadness that the family and the Institute for Plastination announce the passing of Dr. Gunther von Hagens, inventor of Plastination and creator of the BODY WORLDS exhibitions. He died on July 24, 2026, at the age of 81.
Dr. Gunther von Hagens, Inventor of Plastination & Creator of the BODY WORLDS exhibitions, 1945-2026
Gunther von Hagens fundamentally transformed the field of anatomy. Through Plastination—the preservation technique he invented in 1977—he created an entirely new perspective of the human body for medical education, science and the general public. He made the complexity, vulnerability and beauty of the human body—previously reserved for the dissection room and anatomical textbooks –directly accessible to the wider public.
Together with his wife and curator, Dr. Angelina Whalley, Gunther von Hagens created BODY WORLDS, one of the most successful exhibitions in the world. Since its debut, the exhibition has been visited by more than 58 million people. BODY WORLDS made anatomy publicly accessible, encouraged reflection on health, disease, lifestyle and mortality, and inspired millions of people understand and appreciate their own bodies.
“Gunther wanted to give people the opportunity to look beneath the skin — not out of sensationalism, but from the deep conviction that knowledge of one’s own body can contribute to a more conscious, healthier responsible life,” says Angelina Whalley. “His work was scientific, educational and deeply humanistic. He enabled millions of people to see their own bodies in a new light.”
His son, Rurik von Hagens, also honors his father’s life’s work, “My father never accepted that boundaries were fixed. He brought anatomy out of the closed world of specialists and into society. His courage, his perseverance and his unwavering belief that education serves humanity will continue to guide us.”
Gunther von Hagens was a pioneer, researcher, inventor and creator. His life’s work united scientific precision with exceptional craftsmanship, artistic expression and a strong commitment to education. He was an unconventional and often provocative thinker who sparked heated debates, overcame resistance and understood anatomy as an encounter with life itself.
Body donation was always a central part of his work. The human specimens displayed in the BODY WORLDS come from individuals who, during their lifetime, decided to donate their bodies after death for Plastination, scientific research and anatomical education. Gunther von Hagens was deeply grateful to these individuals. He regarded their decision as an extraordinary contribution to education, science and public enlightenment.
It was Gunther von Hagens’ own wish that his body, too, be made available for Plastination after his death. His family will respect and carry out this wish.
Despite serious illness, Gunther von Hagens remained closely connected to his life’s work. The Plastination technique he developed, the Institute for Plastination, the PLASTINARIUM and the BODY WORLDS exhibitions will carry his legacy forward. His scientific and craftsmanship-based legacy lives on in a particularly visible way in Guben. There, at the PLASTINARIUM, anatomical specimens are created for use in the education of physicians and other healthcare professionals at universities, medical schools and educational institutions around the world.
Today, Plastination itself is used at numerous universities, medical schools and educational institutions worldwide.
In this way, the mission Gunther von Hagens began nearly five decades ago continues far beyond BODY WORLDS:
to preserve anatomy permanently, to make it visible, and to make it accessible for science, teaching and public education.
The family kindly asks that their privacy be respected during this time of mourning.
The issuer is solely responsible for the content of this announcement.
About Dr. Gunther von Hagens
Dr. Gunther von Hagens was born on January 10, 1945, in Alt-Skalden, in what is now Poland, and grew up in the GDR. After studying medicine, he invented Plastination at the University of Heidelberg in 1977—a technique for the permanent preservation of biological specimens. In 1993, he founded the Institute for Plastination in Heidelberg, followed in 2006 by the PLASTINARIUM in Guben, which has for many years served as the central laboratory facility for Plastination. With the BODY WORLDS exhibitions, he made human anatomy accessible to audiences around the world. His work transformed anatomical education and became one of the most recognized intersections of science, medicine and public exhibition in the world.
CHENGDU, China, July 27, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK) today announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for its novel dual-payload ADC drug, SKB565, for the treatment of advanced solid tumors. This marks the Company’s first dual-payload ADC to enter the clinical stage.
SKB565 is developed using the Company’s proprietary OptiDC™ platform. Featuring an innovative dual-payload design, SKB565 enables the direct delivery of toxins and immunomodulators, two kinds of payload with complementary mechanisms of action, to tumor tissue. Compared with conventional ADCs carrying only toxins, SKB565 has a dual antitumor mechanism: it precisely targets and kills tumors while activating the immune system within the tumor microenvironment to elicit an antitumor immune response, bringing enhanced and more durable antitumor efficacy. In preclinical studies, SKB565 demonstrated excellent antitumor activity and safety, with its outstanding therapeutic potential to support further clinical development.
Leveraging technological expertise and platform advantages in the ADC field, Kelun-Biotech has established a diversified pipeline of innovative molecules featuring high-value targets, differentiated designs, and global potential. Building on this foundation, the Company continues to advance its “ADC + IO” strategy—on one hand by actively exploring high-quality combination regimens, including multiple ongoing clinical studies evaluating ADCs in combination with PD-(L)1 monoclonal antibodies, as well as the PD-1/VEGF bispecific antibody SKB118 in combination with its proprietary ADC portfolio; on the other hand, the Company is advancing integrated drug design strategies by incorporating synergistic functional components into a single ADC molecule.
Dr. Michael Ge, CEO of Kelun-Biotech, said, ” SKB565 is one of the core representative drugs of our integrated ‘ADC + IO’ strategy, leveraging the synergistic mechanism of its dual payloads to enhance efficacy and overcome drug resistance. Dual-payload ADCs are emerging as one of the key next-generation innovations in the ADC field. The advancement of SKB565 into clinical stage not only marks an important milestone in the achievements transformation of our technology platform, but also substantiates the continued deepening of our innovation capabilities in ADCs. We will actively advance the clinical development of novel drug conjugates such as SKB565, striving to deliver greater benefits to patients with cancer as soon as possible.”
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.
Saguenay-Lac-Saint-Jean, Québec – Newsfile Corp. – July 27, 2026 – First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) (“First Phosphate“) is pleased to announce that its Bégin-Lamarche igneous rock phosphate mining project has been selected for “Filon” support status with the Quebec Ministry of Natural Resources and Forests (“MRNF”), an initiative aimed at accelerating mining projects in Quebec.
The objective of the MRNF’s Filon support is to foster a common understanding of the Bégin-Lamarche phosphate mining project with a view to accelerate its key development milestones. The specialized support to be provided to First Phosphate is intended to facilitate discussions with the government departments and agencies responsible for issuing mining authorizations or permits.
“With the Bégin-Lamarche project, Québec is transforming its geological potential into an economic advantage. By developing a high-purity phosphate deposit intended for the battery sector, we are helping to build a more innovative, more resilient economy focused on future markets. Filon will advance this structural project through a specialized support mechanism.”
Kateri Champagne Jourdain, Québec Minister of Natural Resources and Forests
“We appreciate that the Government of Québec has granted accelerated status to our Bégin-Lamarche igneous rock phosphate project,” said John Passalacqua, CEO of First Phosphate. “Our project holds significant strategic value in helping to onshore the lithium iron phosphate (“LFP”) battery supply chain in North America.”
Announced as part of the Québec Strategy for the Development of Critical and Strategic Minerals 2025-2031, Filon targets critical and strategic mineral projects in Quebec.
The scientific and technical information relating to First Phosphate contained in this press release has been reviewed and approved by Steeve Lavoie, P.Geo., Chief Geologist of First Phosphate, who is a Qualified Person within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).
About First Phosphate Corp. First Phosphate (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) is a mineral exploration and development and clean technology company dedicated to building and reshoring a vertically integrated mine-to-market supply chain for the production of LFP batteries in North America. Target markets include energy storage, data centers, robotics, mobility, and national security. First Phosphate’s flagship Bégin-Lamarche property, located in Saguenay-Lac-Saint-Jean, Québec, Canada, represents a rare North American igneous phosphate resource producing high-purity phosphate characterized by very low levels of impurities.
For additional information Armand MacKenzie President Tel: +1 (514) 618-5289
This release includes certain statements that may be deemed “forward-looking information”. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In particular, this press release contains forward-looking information relating to, among other things: the Company’s participation in the Filon program, the support to be provided and the expected outcomes.
Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, development and exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions that engineering and construction timetables and capital costs for the Company’s, exploration, development and expansion projects are correctly estimated and not affected by unforeseen circumstances; the ability to obtain financing for its proposed operations on acceptable terms; no material deterioration in general business and economic conditions; no material delays in obtaining permits and other approvals; no significant disruptions affecting the activities of the Company or its ability to access required project equipment and services, and operating supplies in sufficient quantities and on a timely basis; inflation and prices for Company project inputs being approximately consistent with anticipated levels; the ability to complete the exploration and development programs consistent with the Company’s expectations; commodity price expectations including assumptions for P2O5; the Company’s relationship with local municipalities and First Nations remaining consistent with the Company’s expectations; the Company’s relationship with other third-party partners and suppliers remaining consistent with the Company’s expectations; and government relations and actions being consistent with Company expectations. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. The Company does not assume any obligation to update or revise its forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law. All forward-looking information contained in this release is qualified by these cautionary statements.
The issuer is solely responsible for the content of this announcement.
SINGAPORE, July 27, 2026 /PRNewswire/ — AMRO released its July 2026 Quarterly Update of the ASEAN+3 Regional Economic Outlook (AREO) today, projecting the ASEAN+3 region to grow by 4.1 percent in 2026, up from its June forecast of 4.0 percent, before moderating slightly to 4.0 percent in 2027. Headline inflation is projected at 1.6 percent in 2026, down from 1.8 percent previously, reflecting lower global commodity price assumptions.
The upgraded outlook reflects sustained momentum in the region’s technology sector, particularly robust demand for semiconductors and other AI-related products, alongside a more favorable global commodity price outlook. Firm household spending, resilient investment, and robust semiconductor and electronics exports are expected to continue driving growth. Energy and industrial input supply disruptions proved less severe than initially feared, with manufacturing activity continuing to expand.
“ASEAN+3 has remained resilient, supported by firm domestic demand and its central role in global AI supply chains,” said AMRO Chief Economist Dong He. “The impact of the Middle East conflict has also been less severe than initially expected, although elevated energy and input costs continue to pose risks to inflation and industrial activity.”
Inflationary pressures have remained broadly contained, with price increases concentrated mainly in energy and transport, while core inflation has risen only modestly. However, food inflation could rise as higher input costs and adverse weather conditions feed through to prices.
AMRO noted that the outlook remains subject to significant uncertainty. Renewed escalation in the Middle East conflict could raise energy, shipping, and food costs, while weaker-than-expected technology demand could weigh on regional exports and investment. Given the importance of AI-related demand to the regional outlook, even a moderate slowdown in global technology investment – to its 2024 pace – could slow ASEAN+3 growth to 2.5 percent in 2027, its weakest rate since the Asian Financial Crisis, excluding the pandemic years. Financial market volatility and rising trade protectionism could further weigh on the outlook.
“The wide range of plausible outcomes underscores the importance of continued vigilance and sound macroeconomic policies,” He added. “Policymakers will need to respond flexibly to differing domestic conditions and rapidly evolving external risks, particularly the AI cycle and the Middle East conflict.”
Further details are available in AMRO’s July 2026 Quarterly Update of the ASEAN+3 Regional Economic Outlook. The next update will be released on October 5.
– ENDS –
About AMRO
AMRO is an international organization established to support macroeconomic resilience and financial stability of the ASEAN+3 region, comprising members of the Association of Southeast Asia Nations (ASEAN) and China; Hong Kong, China; Japan; and Korea. AMRO’s mandate is to conduct macroeconomic surveillance, support regional financial arrangements, and provide technical assistance to the members. AMRO also serves as a regional knowledge hub and provides support to ASEAN+3 financial cooperation.
